News & Events

Billerica, MA (May 1, 2008) – BD Biosciences – Discovery Labware announced today that it has entered into an exclusive worldwide supply agreement with 3-D Matrix, Ltd. (3DM) to distribute 3DM’s PuraMatrix™ products for research applications. Financial terms of the agreement were not disclosed.

The BD™ PuraMatrix™ Peptide Hydrogel is a synthetic biomaterial used to create defined three-dimensional (3-D) microenvironments for a variety of cell types and experimental model systems. Additional research products are planned for 2009, including self-assembling peptides with bioactive motifs.

“We are pleased to be working with 3DM to provide this important life science research tool to advance 3D cell culture,” said Ellen Cunniff, Worldwide Vice President and General Manager, BD Biosciences – Discovery Labware. “The technology augments our BD Falcon™ and BD BioCoat™ surface portfolio by providing innovative synthetic, chemically defined, animal–free surfaces that mimic biological environments that promote cell attachment, growth and differentiation.”

When BD PuraMatrix Peptide Hydrogel is exposed to physiological salt conditions, the peptide component self assembles into a 3D hydrogel that exhibits a nanometer scale fibrous structure. In the presence of key bioactive molecules, this hydrogel promotes the attachment and differentiation of multiple cell types. BD PuraMatrix Peptide Hydrogel is biocompatible, resorbable, injectable and devoid of animal-derived material and pathogens.

3DM is a privately-held, Tokyo-based company focused on regenerative medicine and commercializing a self assembling peptide technology under an exclusive worldwide license granted by the Massachusetts Institute of Technology.

About BD

BD, a leading global medical technology company that manufactures and sells medical devices, instrument systems and reagents, is dedicated to improving people’s health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. For more information, please visit www.bd.com.

###